Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golexanolone in primary biliary cholangitis with fatigue and cognitive dysfunction
ISRCTN67592622Phase 2Active, not recruiting
- Sponsor
- Umecrine Cognition
- Start
- Apr 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of golexanolone in primary biliary cholangitis (PBC), sponsored by Umecrine Cognition. Primary endpoints: Adverse events, Safety laboratory parameters and 1 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
golexanolone
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on ISRCTN67592622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN67592622.